Made available in DSpace on 2015-04-14T13:35:45Z (GMT). No. of bitstreams: 1
450246.pdf: 1514408 bytes, checksum: 6ceddb0f6677e9485ec44236c23b7b0b (MD5)
Previous issue date: 2013-03-25 / The spinal cord injury (SCI) is a condition that dramatically affects the quality of life of affected patients, has a high incidence and causes a high cost to the government and society. Existing treatments for SCI are only palliative nature, not being able to reverse the neurological damage caused by trauma. As a result, it is necessary to investigate new therapies that seek more effective solutions for these cases. The studies with bone marrow mononuclear cells (BMMC) have shown encouraging results, but still not definitive for clinical application, so the expansion of preclinical studies is essential. In this study we aimed to compare treatment outcomes between groups with 3 and 5 applications BMMC applications, analyzing motor function, and inflammation at the lesion site after treatment with BMMC by subarachnoid through via lumbar puncture. The experimental groups were divided into two groups, with different times of transplantation. A group of 3 applications of BMMC, the first application 48 hours, 9 days and 16 days after SCI and a second group with 5 BMMC applications, application in the first 48 hours, 9, 16, 23 and 30 days after by spinal cord injury. The BMMC of male wistar rats was applied via subarachnoid. The entire group received vehicle (saline). The animals were evaluated for motor function through the BBB scale, for the presence of BMMC in the lesion by PCR for the presence of Y chromossome of the cells, and the inflammatory process at the site of injury, analyzing IL-1β and TNF-α, by immunohistochemistry. Our results show an improvement in motor function in the groups treated with BMMC transplants. The immunohistochemical evaluation revealed no difference in the expression of inflammatory cytokines Il-1β and TNF-α at the site of injury in the groups treated with BMMC. The PCR analysis for the presence of chromossome of the cells was negative at the 37th day of the last application of BMMCs / O trauma-raquimedular (TRM) ? uma patologia que afeta drasticamente a qualidade de vida dos pacientes acometidos, apresenta alta incid?ncia e ocasiona um alto custo para o governo e a sociedade. Os tratamentos existentes para o TRM s?o apenas de cunho paliativo, n?o sendo capazes de reverter o dano neurol?gico ocasionado pelo trauma. Em fun??o disso, ? necess?rio investigar novas terapias que busquem solu??es mais efetivas para esses pacientes. Os estudos com c?lulas-tronco de medula ?ssea (CMMO) t?m demonstrado resultados animadores, mas ainda n?o definitivos para aplica??o cl?nica; assim, a amplia??o dos estudos pr?-cl?nicos ? indispens?vel. Neste estudo tivemos o objetivo de comparar os resultados do tratamento de CMMO pela via subaracnoidea (VS) atrav?s de pun??o lombar (PL), entre grupos com 3 aplica??es e 5 aplica??es de CMMO, analisando a fun??o motora e o processo inflamat?rio no local da les?o. Nossos grupos experimentais de estudo foram divididos em 2 grupos pela via de administra??o subaracn?idea, com tempos de transplante diferentes. Um grupo com 3 aplica?oes de CMMO, sendo a primeira aplica??o em 48h, 9 dias e 16 dias ap?s a les?o medular (LM) e um segundo grupo com 5 aplica??es de CMMO, primeira aplica??o em 48 h, 9, 16, 23 e 30 dias ap?s a Les?o Medular (LM) pela VS e cada grupo com seu controle de ve?culo, solu??o salina (SS). Os animais doadores eram machos e os receptores eram f?meas. As ratas foram avaliadas quanto ? fun??o motora, atrav?s da escala de Basso, Beattie and Bresnahan (BBB), quanto ? presen?a de CMMO na les?o, por meio da Rea??o em Cadeia da Polimerase (PCR) para a detec??o do cromossomo Y dos animais doadores, e quanto ao processo inflamat?rio no local da les?o, analisando a interleucina 1 beta (IL-1β) e o fator de necrose tumoral alfa (TNF-α), atrav?s de imuno-histoquimica. Nossos resultados demonstraram uma melhora da fun??o motora nos grupos tratados com transplantes de CMMO, sendo mais r?pida nos animais que receberam 7 cinco aplica??es. A avalia??o imuno-histoqu?mica revelou que n?o houve diferen?a na express?o das citocinas inflamat?rias IL-1β e TNF-α no local da les?o nos grupos tratados com CMMO. A an?lise de PCR n?o demonstrou c?lulas no local da les?o, quando analisadas no 37? dia
| Identifer | oai:union.ndltd.org:IBICT/oai:tede2.pucrs.br:tede/1740 |
| Date | 25 March 2013 |
| Creators | Bonatto, Francine Aurora |
| Contributors | Costa, Jaderson Costa da |
| Publisher | Pontif?cia Universidade Cat?lica do Rio Grande do Sul, Programa de P?s-Gradua??o em Medicina e Ci?ncias da Sa?de, PUCRS, BR, Faculdade de Medicina |
| Source Sets | IBICT Brazilian ETDs |
| Language | Portuguese |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, info:eu-repo/semantics/masterThesis |
| Format | application/pdf |
| Source | reponame:Biblioteca Digital de Teses e Dissertações da PUC_RS, instname:Pontifícia Universidade Católica do Rio Grande do Sul, instacron:PUC_RS |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | 7620745074616285884, 500, 600, -8624664729441623247 |
Page generated in 0.0024 seconds